RE: will £5 be broken again this week11 May 2020 22:10
also like this in 29 April RNS
Graham Mullis, Chief Executive Officer of Novacyt, commented:
"The visibility of the sales order book is transformational for the business and it is becoming increasingly clear that this exceptional demand for our COVID-19 test could continue for some months. As a result, we continue to ensure we have significant capacity and flexibility in the manufacturing of our COVID-19 test.
"I am proud that innovation remains at the heart of the business and the forthcoming launch of our Exsig™ Free extraction kit will address a significant market need to increase testing availability and throughput. This is a challenging time for Novacyt but the transformation of our financial performance and our position as a market leader in clinical diagnostics means we are confident in the long-term prospects of the business."
Novacyt is now supplying its COVID-19 test to more than 100 countries and approvals for the test have recently been received from Malaysia and Ecuador.
Novacyt is now supplying its COVID-19 test to more than 100 countries and approvals for the test have recently been
received from Malaysia and Ecuador.
ALSO THINKING NEWS UPDATE SOON
maybe this week
Partnership with AZ, GSK & University of Cambridge
Notification of 2019 final results
Due to a longer review process of the financial statements caused by COVID-19, the Company now intends to report its audited results for the year ended 31 December 2019 during the week commencing 11 May 2020.
The development of a new "direct-to-PCR" extraction method, Exsig™ Free, used prior to running the Company's COVID-19 test,
Development is progressing well and Novacyt is on track to launch this new extraction technology in May 2020.
90 million
As of 28 April 2020, Primerdesign has sold, received orders for or has been contracted to deliver over £90 million (€103 million) of its COVID-19 test. This figure includes the contracted minimum amount of test orders from the recently signed supply agreement with the UK's Department of Health and Social Care and initial orders received to date from the collaboration with AstraZeneca, GSK and the University of Cambridge
so much news at this share
how long can this SHARE PRICE STAY THIS LOW WITH SO MUCH NEWS
will this week .
or this month see this share price move up to £6 or £ 7
Sign In
Follow the stocks
